Overview

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Antibodies, Monoclonal
Ofatumumab